EDITOR'S CHOICE NEWS Winners: Witney shops 1,051 Witney homes are still at risk Cogges Manor Farm Museum decision delayed until October FOOTBALL FOOTBALL: Lewis on the mark as Witney start with draw HELEN'S PUBS The Marlborough, Witney: Overlooking Market Square CINEMA Lars and the Real Girl, Garage and Son of Man VOTE Do you agree that small independent shops make Witney more attractive? YES NO GET OUR NEWS BY E-MAIL Just register

Most read Comments 1 Eco-town approach may be unlawful 2 Singer 'fought Johnny Rotten' 3 £156m boost for science 4 Land Girls reap praise from PM 5 Radiohead in running for Mercury 6 Mothers call for new law 7 Lidl store plan rejected 8 Police stop drivers in roadside checks 9 CRICKET: OCA League results & fixtures 10 Life for groom who set fire to best man Today | 7 Days 1 Go-slow hit by no-show 2 Trapped dog freed from mine shaft 3 New TV news programme launched 4 FLOOD ONE YEAR ON: 'Never say never again' 5 Radio audience dips 6 Lidl store plan rejected 7 Longest serving shopkeeper dies 8 Murderer faces life behind bars 9 Lucy storming in Gladiators 10 Crash death victims named

Taking the chair: Alan Kingsman

The board of a pioneering biotech firm is undergoing a major shake-up with its co-founder retiring from her senior role.

Professor Susan Kingsman will step down from her position as chief scientific officer and executive director of Oxford Biomedica, while her partner, Professor Alan Kingsman, will move from chief executive to chairman.

Current non-executive director Dr Peter Johnson will retire with Dr Mike McDonald moving from chief medical officer to chief executive.

Alan Kingsman said: "I look forward to working with Mike, as we take Oxford BioMedica to its next stage of corporate and commercial success."

Mr Johnson added: "It has been a great pleasure being part of the team at Oxford BioMedica that has seen the company progress from an early-stage research organisation to become a leading UK biopharmaceutical company."

Oxford Biomedica, based at the Oxford Science Park, is set to launch its first cancer drug, TroVax, for the treatment of advanced kidney cancer in about 18 months time.

The product has also been successfully tested on bowel and prostate cancer sufferers.

Dr Stuart Naylor, currently senior vice president, research and development, will take Susan Kingsman's place on the board. She will continue to work for the company she helped set up in 1995 as a senior scientific consultant.

Nick Rodgers, the company's senior independent director, will step up to become deputy chairman.

The changes will take effect on July 1.

11:43am Tuesday 15th April 2008

Print

Email this